See more : Bellevue Gold Limited (BGL.AX) Income Statement Analysis – Financial Results
Complete financial analysis of LifeMD, Inc. (LFMD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of LifeMD, Inc., a leading company in the Medical – Pharmaceuticals industry within the Healthcare sector.
- Melcor Developments Ltd. (MRD.TO) Income Statement Analysis – Financial Results
- Shanghai Industrial Urban Development Group Limited (0563.HK) Income Statement Analysis – Financial Results
- Lagardere SA (MMB.PA) Income Statement Analysis – Financial Results
- Community Healthcare Trust Incorporated (CHCT) Income Statement Analysis – Financial Results
- Lennar Corporation (LEN-B) Income Statement Analysis – Financial Results
LifeMD, Inc. (LFMD)
About LifeMD, Inc.
LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for care across various indications, including concierge care, men's sexual health, dermatology, and others in the United States. The company provides ShapiroMD, a telehealth platform brand that offers access to virtual medical treatment, prescription medications, patented-doctor formulated OTC products, and an FDA approved medical device for male and female hair loss, and female specific topical compounded medications for hair loss; RexMD, a men's telehealth brand that offers virtual medical treatment from licensed providers for a variety of men's health needs; LifeMD Primary Care, a personalized subscription-based virtual primary care platform that provides patients with primary care, urgent care, and chronic care needs, as well as .offers a mobile first platform that incorporates virtual consultations and treatment, prescription medications, diagnostics, and imaging; Cleared, a telehealth brand that provides personalized treatments for allergy, asthma, and immunology; and Nava MD, a female-oriented tele-dermatology and skincare brand that offers virtual medical treatment from dermatologists and other providers. It also offers PDFSimpli, an online software-as-a-service platform that allows users to create, edit, convert, sign, and share PDF documents. LifeMD sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was founded in 1994 and is headquartered in New York, New York.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 152.55M | 119.03M | 92.88M | 37.29M | 12.47M | 8.32M | 5.05M | 5.24M | 1.22M | 714.16K | 808.36K | 673.78K | 743.83K |
Cost of Revenue | 18.90M | 18.67M | 18.00M | 8.91M | 3.27M | 1.97M | 1.48M | 1.95M | 247.77K | 172.85K | 181.30K | 125.62K | 241.26K |
Gross Profit | 133.65M | 100.37M | 74.88M | 28.39M | 9.20M | 6.36M | 3.57M | 3.29M | 971.09K | 541.31K | 627.06K | 548.16K | 502.56K |
Gross Profit Ratio | 87.61% | 84.32% | 80.62% | 76.12% | 73.77% | 76.35% | 70.65% | 62.85% | 79.67% | 75.80% | 77.57% | 81.36% | 67.56% |
Research & Development | 6.06M | 2.97M | 778.77K | 446.75K | 222.88K | 120.54K | 0.00 | 0.00 | 23.93K | 0.00 | 0.00 | 0.00 | 0.00 |
General & Administrative | 51.69M | 46.96M | 39.57M | 42.21M | 2.40M | 3.33M | 2.98M | 2.76M | 978.72K | 1.07M | 1.17M | 1.09M | 1.08M |
Selling & Marketing | 76.45M | 78.37M | 82.54M | 41.67M | 8.17M | 5.08M | 1.66M | 1.71M | 230.66K | 57.25K | 0.00 | 0.00 | 0.00 |
SG&A | 128.15M | 125.33M | 122.11M | 83.88M | 10.57M | 8.41M | 4.64M | 4.47M | 1.21M | 1.07M | 1.17M | 1.09M | 1.08M |
Other Expenses | 13.93M | 11.75M | 6.29M | 1.88M | 1.30M | -516.98K | 215.13K | 0.00 | 0.00 | 57.88K | 54.33K | 80.55K | 77.50K |
Operating Expenses | 148.46M | 140.05M | 129.18M | 86.21M | 12.09M | 8.41M | 4.64M | 4.47M | 1.23M | 1.07M | 1.17M | 1.09M | 1.08M |
Cost & Expenses | 167.04M | 158.72M | 147.18M | 95.11M | 15.36M | 10.38M | 6.12M | 6.41M | 1.48M | 1.25M | 1.35M | 1.21M | 1.32M |
Interest Income | 0.00 | 1.28M | 3.02M | 1.67M | 761.15K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 2.60M | 1.28M | 3.02M | 1.67M | 761.15K | 354.39K | 100.52K | 48.61K | 37.48K | 4.68K | 3.39K | 3.37K | 21.26K |
Depreciation & Amortization | 6.60M | 3.77M | 868.76K | 397.77K | 335.61K | 195.78K | 1.23M | 43.75K | 43.75K | 56.98K | 56.97K | 56.97K | 56.69K |
EBITDA | -8.21M | -39.61M | -53.95M | -57.48M | -2.55M | -1.86M | -138.43K | -1.17M | -91.21K | -416.02K | -225.10K | -402.50K | -442.18K |
EBITDA Ratio | -5.38% | -27.07% | -53.23% | -155.04% | -20.48% | -11.23% | -21.12% | -22.42% | -17.92% | -66.36% | -60.55% | -71.69% | -69.87% |
Operating Income | -14.49M | -39.69M | -54.30M | -57.82M | -2.89M | -2.06M | -1.07M | -1.17M | -262.22K | -530.88K | -546.41K | -540.03K | -576.37K |
Operating Income Ratio | -9.50% | -33.34% | -58.47% | -155.04% | -23.18% | -24.70% | -21.12% | -22.42% | -21.51% | -74.34% | -67.59% | -80.15% | -77.49% |
Total Other Income/Expenses | -2.92M | -4.97M | -7.02M | -2.58M | -761.15K | -354.39K | -150.92K | -48.61K | 89.79K | 53.19K | 260.95K | 77.18K | 56.24K |
Income Before Tax | -17.41M | -44.66M | -61.32M | -60.40M | -3.65M | -1.48M | -1.22M | -1.22M | -172.43K | -477.69K | -285.46K | -462.85K | -520.13K |
Income Before Tax Ratio | -11.41% | -37.52% | -66.02% | -161.96% | -29.28% | -17.84% | -24.11% | -23.35% | -14.15% | -66.89% | -35.31% | -68.69% | -69.93% |
Income Tax Expense | 428.00K | 360.70K | 7.70K | 122.50K | -122.50K | -124.70K | -12.49K | -115.75K | -13.20K | -17.20K | -17.20K | -17.20K | -17.20K |
Net Income | -20.60M | -45.02M | -61.32M | -60.52M | -3.53M | -1.24M | -1.21M | -1.11M | -61.99K | -460.49K | -268.26K | -445.65K | -502.93K |
Net Income Ratio | -13.50% | -37.82% | -66.03% | -162.29% | -28.30% | -14.91% | -23.86% | -21.14% | -5.09% | -64.48% | -33.19% | -66.14% | -67.61% |
EPS | -0.70 | -1.45 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.08 | -0.05 | -0.08 | -0.07 |
EPS Diluted | -0.70 | -1.45 | -2.27 | -4.24 | -0.36 | -0.14 | -0.14 | -0.16 | -0.01 | -0.07 | -0.04 | -0.08 | -0.07 |
Weighted Avg Shares Out | 33.91M | 30.98M | 27.01M | 14.28M | 9.90M | 8.84M | 8.80M | 7.05M | 6.16M | 6.07M | 5.88M | 5.50M | 7.52M |
Weighted Avg Shares Out (Dil) | 33.91M | 30.98M | 27.01M | 14.28M | 9.90M | 9.05M | 8.80M | 7.05M | 6.40M | 6.15M | 6.02M | 5.78M | 7.52M |
LifeMD to Participate in Panel Presentation at LifeSci Partners Corporate Access Event 2022
LifeMD to Participate in the Stephens Annual Investment Conference
5 Reasons Why I'm Long LifeMD And You Should Be Too
LifeMD, Inc. (LFMD) CEO Justin Schreiber on Q3 2021 Results - Earnings Call Transcript
LifeMD, Inc. (LFMD) Reports Q3 Loss, Tops Revenue Estimates
New Preferred Stock IPOs, October 2021
LifeMD to Release Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
LifeMD Announces Closing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock
LifeMD Announces Closing of Public Offering of Common Stock and Exercise of the Underwriters' Option
LifeMD Announces Pricing of Public Offering 1,400,000 Shares of 8.875% Series A Cumulative Perpetual Preferred Stock
Source: https://incomestatements.info
Category: Stock Reports